DXM Distribution Legislation Clears House And Moves To Senate Again
This article was originally published in The Tan Sheet
Executive Summary
Legislation banning distribution of bulk dextromethorphan to people and businesses not registered with FDA passed the House with overwhelming support and moves to the Senate, where similar bills stalled in the two previous sessions
You may also be interested in...
In Brief
Plan B One-Step gets generic competition; legislation to restrict DXM introduced again; J&J agrees to reforms in settlement; China recants on MJN formula concerns; Buster line drives Hi-Tech Pharmacal OTC growth; Sabinsa awarded profits from infringed ForsLean trademark; more news In Brief.
Elections Reshape FDA Oversight Scene On Capitol Hill
The Republican takeover in the House shuffles the leadership in committees crucial to the dietary supplement and OTC drug industries while likely setting the stage for cuts to FDA funding.
Elections Reshape FDA Oversight Scene On Capitol Hill
The Republican takeover in the House shuffles the leadership in committees crucial to the dietary supplement and OTC drug industries while likely setting the stage for cuts to FDA funding.